Liquidia Corporation (LQDA) shares climbed 12.3% to $47.38 as of November 4, 2026, a sharp gain from the prior close of $42.20. BestStocks flagged the session as a major change for LQDA. The move is tied to price move up. Below, we break down what changed for LQDA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
LQDA climbed 12.3% to $47.38
Liquidia Corporation (LQDA) moved +9.37% from $43.32 to $47.38 on November 4, 2026, reaching a new 30-day high on volume 2.0x the 5-day average. The company is scheduled to report Q3 2026 financial results on November 10, 2026. Liquidia's Q3 2026 earnings report on November 10, 2026, and actual EPS versus the $0.96 consensus estimate.
This summary describes the catalyst and move as first detected on Nov 4, 2026, 4:43 PM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsMedium confidence
Rel. volume
1.7×
Above Avg
Vs peers
—
No comparable peers
Market cap
$4.2B
NASDAQ Capital Market
Analyst target
$72
+52.7% vs price
Price chart
Oct 5 – Nov 4
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Liquidia Corporation investors
For Liquidia Corporation investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 12.3% price move with conviction. Weighing against that: Liquidia Corporation (LQDA) moved −8.44% from $45.71 to $41.85 on November 2, 2026; Liquidia Corporation fell 15.16% to $25.67 after filing a material event (8-K) with the SEC today. Wall Street's consensus price target sits at $72.36, implying +52.7% upside from $47.38. Over the past 90 days analysts logged 2 upgrades and 4 downgrades. BestStocks rates the overall signal quality medium (64/100). With earnings roughly 6 days out, the next report is the most likely near-term test of the move.
LQDA price reaction
LQDA last traded at $47.38, up $5.18 (+12.27%) from the previous close of $42.20. The session traded on 1.7× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $25.91 and $47.38, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Liquidia Corporation (LQDA)
▲Latest catalyst·strengthens the bull case
The latest catalyst — a materially positive development — it strengthens the bull case.
The consensus analyst price target on Liquidia Corporation (LQDA) is $72.36, 52.7% above the recent $47.38. Over the past 90 days analysts logged 2 upgrades, 9 maintains, and 4 downgrades. Here is how the bullish and bearish cases on LQDA line up.
▲ The bullish case
+Wall Street's consensus price target of $72.36 implies +52.7% upside from $47.38.
+The Street's most bullish target is $130.00 (+174.4%).
+2 analyst upgrades in the past 90 days, most recently LifeSci Capital to Outperform (2026-10-14).
+Material positive event.
+Strong 12.3% price move with conviction.
▼ The bearish case
−The most bearish analyst target is $33.00 (-30.4%).
−4 analyst downgrades in the past 90 days, most recently Wells Fargo to Equal Weight (2026-10-02).
−Liquidia Corporation (LQDA) moved −8.44% from $45.71 to $41.85 on November 2, 2026.
−Liquidia Corporation fell 15.16% to $25.67 after filing a material event (8-K) with the SEC today.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
The latest catalyst moved the balance toward the bulls — the hollow tick marks where it sat before.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 4, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Liquidia scheduled Q3 2026 financial results release for November 10, 2026.
Risk2026-11-02-7.1%
Liquidia Corporation (LQDA) moved −8.44% from $45.71 to $41.85 on November 2, 2026. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting the decline occurred on typical trading activity.
Liquidia shares rose 6.06% to $42.09, extending gains from a major settlement with United Therapeutics that resolved all six pending patent, trade secret, and antitrust lawsuits against the company. According to Yahoo Finance and Investing.com, the agreement eliminated the threat of an injunction against Yutrepia (inhaled treprostinil), clearing a path for uninterrupted commercialization of its flagship pulmonary arterial hypertension drug. Volume remained below average at 0.44x the typical intraday pace.
Liquidia shares gained 6.05% to $38.55, continuing momentum from its October 14 global settlement with United Therapeutics that resolved patent litigation and cleared a major commercial risk for YUTREPIA (per web_catalyst synthesis). The $380.7 million settlement removed the litigation overhang; H.C. Wainwright subsequently raised its price target to $65. Volume of 1.8M shares is below average (0.44x) at this point in the session.
Material / Earnings2026-10-20+6.5%
Liquidia Corporation (LQDA) moved +7.23% to $36.35 on October 20, 2026, continuing a rally following its October mid-month announcement of a $380.7 million global settlement with United Therapeutics that resolved all six pending lawsuits. The settlement clears litigation risk and secures uninterrupted U.S. commercial sales of YUTREPIA, its pulmonary arterial hypertension treatment. HC Wainwright raised its price target to $65 from $58 following the legal resolution.
Activity2026-10-14+26.6%
Liquidia Corporation filed a material event 8-K today, prompting a sharp 27.71% intraday rally from $26.81 to $34.24. The specific content of the 8-K was not immediately disclosed in available sources, but the filing triggered immediate buying pressure at the open of the trading session.
News2026-10-13-3.1%
Liquidia settles all pending litigation with United Therapeutics, securing uninterrupted YUTREPIA commercialization rights.
Material / Earnings2026-10-12+1.1%
Liquidia Corporation (LQDA) moved -5.61% from $29.32 to $27.67 on October 12, 2026, continuing a decline that began in late September after a federal court ruled that the company's inhaled drug Yutrepia infringes two valid patent claims held by United Therapeutics related to treating pulmonary hypertension with interstitial lung disease. Following the adverse ruling, multiple analysts including BTIG and Needham & Company cut their ratings and lowered price targets on LQDA.
In-depth LQDA event analyses
Permanent, dated analyses of LQDA's most significant sessions.
LQDA climbed 12.3% to $47.38. The move is associated with price move up.
How much did LQDA stock rise?
LQDA gained 12.27% ($5.18) versus the prior close of $42.20, last trading at $47.38 on 1.7× average volume.
When is Liquidia Corporation's next earnings date?
LQDA's next earnings report is estimated for 2026-11-10 — about 6 days away.
What is the analyst price target for LQDA?
The consensus analyst price target for LQDA is $72.36, about 52.7% above the current $47.38. Over the past 90 days, analysts recorded 2 upgrades, 9 maintains, and 4 downgrades.
How BestStocks tracks LQDA
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for LQDA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 4, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
